Faysal Yafi, MD Aquablation outcome for the U.S, cohort for men with LUTS due to BPH in large prostates (80-150 cc) International Journal of Impotence Research Jul 2018
Veeru Kasivisvanathan, MD Aquablation versus transurethral resection of the prostate: 1 year United States – cohort outcomes The Canadian Journal of Urology Jun 2018
Mihir Desai, MD WATER II (80–150 mL) procedural outcomes BJU International Apr 2018
Samih Tktak, MD Aquablation: a novel and minimally invasive surgery for benign prostate enlargement Therapeutic Advances in Urology  Feb 2018
Peter Gilling, MD Aquablation for Benign Prostatic Hyperplasia Journal of Videourology Jan 2017
Catriona MacRae, MBBS How I Do It: Aquablation for the prostate using the AquaBeam system Candadian Journal of Urology Dec 2016
Marie Adrianne Pimentel Aquablation: Early Clinical Results Current Bladder Dysfunction Reports Mar 2016

Instruction for Use

The following Instructions for Use are for the United States only. For country-specific Instructions for Use, please contact

PROCEPT BioRobotics is pleased to support providers seeking reimbursement for Aquablation therapy.

The Aquablation Reimbursement Center (ARC) provides individual reimbursement assistance to providers. This HIPAA-secured customer service center offers:

  • Answers to general questions about coding, coverage and payment
  • Submission for prior authorization
  • Facilitation of claims appeal submission

Select from the links below to download additional reimbursement resources:

Hours: Monday-Friday 10AM – 5PM CT
Email and Voice Mail messages returned within one business day
Phone: 833 230 2406
Fax: 650 649 1856

To request assistance with reimbursement questions or prior authorization, please contact us through secure email, fax, or phone.

– – –

Disclaimer: The information provided through this webpage was obtained from third-party sources and is subject to change without notice as a result of changes in reimbursement laws, regulations, rules, policies, and payment amounts. All content is informational only, general in nature, and does not cover all situations or all payers’ rules and policies. It is the responsibility of the hospital or physician to determine appropriate coding for a particular patient and/or procedure. Any claim should be coded appropriately and supported with adequate documentation in the medical record. A determination of medical necessity is a prerequisite that PROCEPT BioRobotics assumes will have been made prior to assigning codes or requesting payments. Any codes provided are examples of codes that specify some procedures or which are otherwise supported by prevailing coding practices. They are not necessarily correct coding for any specific procedure using PROCEPT BioRobotics products.

Hospitals and physicians should consult with appropriate payers, including Medicare Administrative Contractors, for specific information on proper coding, billing, and payment levels for healthcare procedures. PROCEPT BioRobotics makes no express or implied warranty or guarantee that (i) the list of codes and narratives available through these resources is complete or error-free, (ii) the use of this information will prevent difference of opinions or disputes with payers, (iii) these codes will be covered or (iv) the provider will receive the reimbursement amounts set forth herein. Reimbursement policies can vary considerably from one region to another and may change over time.

Accessory Products

PROCEPT BioRobotics is dedicated to developing products and accessories designed to streamline the Aquablation procedure and improve the patient’s experience during and following BPH surgery.

Catheter Tensioning Device (CTD)

The CTD is a custom catheter tensioning device designed for comfortably and reliably securing the urinary catheter for post-operative irrigation and hemostasis. The device is commercially available in the U.S., Europe, Canada, Australia and New Zealand.